| Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
|
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
| A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
|
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
| Management of aplastic anemia after failure of frontline immunosuppression |
|
Expert Review of Hematology |
Aplastic Anemia |
| Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
|
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
| Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
